Table 2.
Clinicopathologic features and clinical outcomes of secretory carcinoma.
| Variables | Secretory carcinoma (N = 22) | Acinic cell carcinoma (N = 36) |
|---|---|---|
| Median age (year) | 34 (mean, 36.5; range, 6–78) | 34 (mean, 37.9; range, 14–68) |
| Male: Female | 14:8 | 14:22 |
| Anatomical distribution | ||
| Parotid gland | 20 (91%)a | 35 (97%) |
| Minor salivary gland | 1 (5%)a | 1 (3%) |
| Submandibular gland | 1 (5%)a | 0 |
| Median tumor size (cm) | 2.2 (mean, 2.3; range: 1.1–3.8) | 2.7 (mean, 2.5; range, 1.0–5.2) |
| Surgery | ||
| Superficial parotidectomy | 13 (59%) | 22 (61%) |
| Total parotidectomy | 7 (32%) | 13 (36%) |
| Mass excision | 2 (9%) | 1 (3%) |
| Lymph-node dissection | ||
| Performed | 11 (50%) | 5 (14%) |
| Not performed | 11 (50%) | 31 (86%) |
| Nodal metastasisb | 4 out of 11 | 0 out of 5 |
| Resection margin involvement | 2 (9%) | 3 (8%) |
| American Joint Committee on Cancer tumor stage | ||
| I (T1N0) | 3 (14%)c | 12 (33%)b |
| II (T2N0) | 14 (64%)c | 21 (58%)b |
| III (T3 or N1) | 5 (23%)c | 3 (8%)b |
| Post operative radiation therapy | 8 (36%) | 5 (14%) |
| Median follow-up period (mo) | 46 (mean, 53.8; range, 6–140) | 48 (mean, 58.5; range, 6–180) |
| Overall recurrence | 7 (32%) | 5 (14%) |
| Recurrence site | ||
| Local | 5 | 3 |
| Nodal | 1 | 0 |
| Local and nodal | 1 | 2 |
| Median recurrence interval (mo) | 24 (mean, 24.5; range: 6–51) | 48 (mean, 46; range: 12–96) |
| Mean disease-free survival (mo) | 99 (95% CI, 74–123) | 153 (95% CI, 128–177) |
| 3-year recurrence ratee | 5/18 (28%) | 2/26 (8%) |
| 5-year recurrence ratee | 7/16 (44%) | 4/17 (24%) |
| Died of disease | 0 (0%) | 0 (0%) |
aThe percentages before rounding are 90.9%, 4.5%, and 4.5%, respectively
bLymph-node metastasis was known only among cases undergoing lymph node dissection. To avoid overestimation, the percentage was not presented in this table
cThe percentages before rounding are 13.6%, 63.6%, and 22.7%, respectively. In 11 patients without node dissection, clinical N stage was considered as cN0
dThe percentages before rounding are 33.33%, 58.33%, and 8.33%, respectively
eThree-year and five-year follow-up data were available for 18 and 16 patients with secretory carcinoma, respectively; and 26 and 17 patients with acinic cell carcinoma, respectively